Update: clinically significant cytochrome P-450 drug interactions.
about
Role of cytochrome P450 in drug interactionsPolytherapy and drug interactions in elderlyThe effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjectsThe effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteersReduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors.Drug interactions and the statins.Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children.Sex differences in drug disposition.Addressing phenoconversion: the Achilles' heel of personalized medicine.Initiating antiretrovirals during tuberculosis treatment: a drug safety review.Determinants of polybrominated biphenyl serum decay among women in the Michigan PBB cohort.Clinical Analysis of Adverse Drug Reactions between Vincristine and Triazoles in Children with Acute Lymphoblastic Leukemia.Transient gene delivery for functional enrichment of differentiating embryonic stem cells.Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady stateNuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters.Quinine induced simvastatin toxicity through cytochrome inhibition - a case report.Analysis of genetic variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 genes using oligonucleotide microarrayChiral metabolism of propafenone in rat hepatic microsomes treated with two inducers.Functional evolution of the pregnane X receptor.Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based Analysis.Comparative cytochrome p450 in vitro inhibition by atypical antipsychotic drugsTreatment of acute tacrolimus toxicity with phenytoin in solid organ transplant recipientsReduced activities of cytochrome P450 1A2 and xanthine oxidase in children with growth hormone deficiencyUse of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: questionnaire validation.Describing the profile of patients on concurrent rifampin and warfarin therapy in western Kenya: a case series.Optimizing chemotherapy: concomitant medication listsThe pharmacological management of migraine, part 1: overview and abortive therapy.Retinoids activate RXR/CAR-mediated pathway and induce CYP3A.Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.Drug interactions: a primer for the gastroenterologistA simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line.Effect of combination of aripiprazole with carbamazepine and fluvoxamine on liver functions in experimental animals.Studies on Pharmacokinetic Drug Interaction Potential of VinpocetineA Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers.A decay model for assessing polybrominated biphenyl exposure among women in the Michigan Long-Term PBB Study.Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agentRosehip inhibits xanthine oxidase activity and reduces serum urate levels in a mouse model of hyperuricemia.Indinavir-fluconazole interaction.Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole
P2860
Q21245066-741F0DCD-B821-4456-A85D-996F9FE15376Q28072737-5052FE91-7F4A-43D0-A75A-207FED29DC48Q28361017-8DBEE184-D66C-491F-B13B-5C96DD6E5497Q28367502-36254364-F589-4A8A-87DB-1C77A00FEEEFQ30515490-F67001E9-B3E3-4DFC-A818-BE4FF6F75AF5Q33786019-B38D8B25-5503-4E98-B7A9-0EA4DF176891Q33977967-2B0B3EC8-BCFC-4354-A183-D76066BED64BQ34635175-AC0780A3-AEE9-433E-9116-17362E6168E8Q35023701-C4F1ADAC-0929-4D30-A657-CFD74CC00D31Q35043048-191AD9F2-F991-48A4-8EAA-122211C8A64BQ35134743-EEAE2255-D58C-4651-9837-9A98E3271494Q35754431-ED68FA41-A148-4381-A45D-57C388AFA865Q35805133-65B7552C-7598-4D1E-A7A8-524E4D254922Q35825990-63002CD0-7E70-4CA8-9804-B8EB286F03B2Q35919726-60250B5D-9233-46E1-A029-DB223A2D7727Q36156619-EF964CB2-93DD-4AC1-8078-D73A17EC3918Q36412046-A9B69737-438F-47AA-B368-B45FEEFE2D81Q36415705-B43FB4D6-618D-49BD-93CA-4123DCD75F6DQ36440155-1309DEE9-ACA3-46E2-B384-25D73ED1DEC4Q36445099-9E4EB806-64E8-4281-90E6-786F59BFF03EQ36651297-A994CFD6-AF97-484F-BEA8-6DAAAFAE14B7Q36969224-549EBE42-611B-411D-9816-4A737AC6F114Q37115549-65B97850-264B-495C-AE5B-E167BD6F10B5Q37130871-D0A6B529-23D6-4798-A715-5BC5D5F701F1Q37199759-8C1E518A-38F6-4DC3-8E1D-CCF326160936Q37304704-F2612DF2-9994-4A55-9B6D-8A75232F9AC2Q37340160-6455D9EE-F896-4076-9056-F6FADD2FA9AEQ37441580-C0A0D89E-E2D8-4389-8459-7C5B317684C1Q37625387-BCAF2F04-BAEF-45D7-BC86-EFCA0C968A3AQ38039067-72F88DC0-2293-4DCE-9317-885FB3FA6153Q40376556-96F83E5D-BDCF-4B27-9275-6CDE991F579EQ40921574-521EC0CF-CFDB-4345-AAC6-82303FC8744BQ41167581-62CD1BCC-56E6-49D7-97FE-22383DABA9A8Q41453985-92A8B832-92E7-4681-B76F-859F941F2EE3Q41589461-5D2DA05C-2A49-4DB4-B3AE-CE8C3DEE2D81Q41668110-BF461782-C51E-412F-9408-E7A2DAAEC034Q42172577-D420EB93-68FD-4DB4-B5B8-D53E57FF275FQ42728535-65BAB54E-4200-4EEC-9359-AFA4E87FBCF6Q42780390-F5B52BC2-3CDF-4C14-8E9E-8D2208905596
P2860
Update: clinically significant cytochrome P-450 drug interactions.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Update: clinically significant cytochrome P-450 drug interactions.
@ast
Update: clinically significant cytochrome P-450 drug interactions.
@en
Update: clinically significant cytochrome P-450 drug interactions.
@nl
type
label
Update: clinically significant cytochrome P-450 drug interactions.
@ast
Update: clinically significant cytochrome P-450 drug interactions.
@en
Update: clinically significant cytochrome P-450 drug interactions.
@nl
prefLabel
Update: clinically significant cytochrome P-450 drug interactions.
@ast
Update: clinically significant cytochrome P-450 drug interactions.
@en
Update: clinically significant cytochrome P-450 drug interactions.
@nl
P1433
P1476
Update: clinically significant cytochrome P-450 drug interactions.
@en
P2093
Michalets EL
P304
P407
P577
1998-01-01T00:00:00Z